FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

BRS Analytical Services Lubricant Eye Drops Solution Recall

Lubricant Eye Drops Solution, Polyethylene Glycol 400 0

BRS Analytical Services, LLC · Saint Louis, MO

Risk level
Class II
Reported by FDA
May 14, 2025
Recall ID
D-0407-2025
Check your lot numberHow we source this data

Summary

BRS Analytical Services recalled Lubricant Eye Drops Solution starting Apr 23, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0407-2025 on May 14, 2025. Reason: cGMP deviations and lack of assurance of sterility. Status: Ongoing.

Why it was recalled

cGMP deviations and lack of assurance of sterility.

Product description

Lubricant Eye Drops Solution, Polyethylene Glycol 400 0.4% Eye Lubricant, Propylene Glycol 0.3% Eye Lubricant, Lubricant Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-126-15.

Lot numbers, UPCs & expiration codes

Lot, expiry: Lot 117, exp 9/20/25; Lot 118, exp 9/25/25; Lot 119, exp 9/27/25; Lot 121, exp 10/05/25; Lot 161, exp 5/01/26; Lot 171, exp 6/18/26; Lot 172, exp 6/24/26; Lot 174, exp 7/01/26; Lot 175, exp 7/08/26; Lot 200, exp 11/05/26; Lot 201, exp 11/10/26; Lot 202, exp 11/13/26; Lot 203, exp 11/18/26; Lot 204, exp 11/21/26; Lot 205, exp 11/25/26; Lot 206, exp 12/02/26; Lot 219, exp 2/24/27; Lot 221, exp 3/02/27; Lot 222, exp 3/05/27.

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0407-2025
Classification
Class II
Status
Ongoing
Recall initiated
Apr 23, 2025
FDA report date
May 14, 2025
Quantity
13,104 cases (24 cartons per case)
Recall type
Voluntary: Firm initiated
Recalling firm
BRS Analytical Services, LLC

Original FDA data

Every field from FDA enforcement report D-0407-2025, exactly as published.

Show all FDA fields
City
Saint Louis
State
MO
Status
Ongoing
Country
United States
Event ID
96741
Address
11697 Lakeside Crossing Ct
Code information
Lot, expiry: Lot 117, exp 9/20/25; Lot 118, exp 9/25/25; Lot 119, exp 9/27/25; Lot 121, exp 10/05/25; Lot 161, exp 5/01/26; Lot 171, exp 6/18/26; Lot 172, exp 6/24/26; Lot 174, exp 7/01/26; Lot 175, exp 7/08/26; Lot 200, exp 11/05/26; Lot 201, exp 11/10/26; Lot 202, exp 11/13/26; Lot 203, exp 11/18/26; Lot 204, exp 11/21/26; Lot 205, exp 11/25/26; Lot 206, exp 12/02/26; Lot 219, exp 2/24/27; Lot 221, exp 3/02/27; Lot 222, exp 3/05/27.
Postal code
63146-8606
Report date
May 14, 2025
Product type
Drugs
Recall number
D-0407-2025
Classification
Class II
Recalling firm
BRS Analytical Services, LLC
Product quantity
13,104 cases (24 cartons per case)
Reason for recall
cGMP deviations and lack of assurance of sterility.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lubricant Eye Drops Solution, Polyethylene Glycol 400 0.4% Eye Lubricant, Propylene Glycol 0.3% Eye Lubricant, Lubricant Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) per dropper bottle, Distributed by: AvKARE, Pulaski, TN 38478, NDC: 50268-126-15.
Distribution pattern
Nationwide in the USA
Recall initiation date
Apr 23, 2025
Initial firm notification
Letter
Center classification date
May 6, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0407-2025, published May 14, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls